» Articles » PMID: 10639442

Absence of SpeB Production in Virulent Large Capsular Forms of Group A Streptococcal Strain 64

Overview
Journal Infect Immun
Date 2000 Jan 20
PMID 10639442
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Passage in human blood of group A streptococcal isolate 64p was previously shown to result in the enhanced expression of M and M-related proteins. Similarly, when this isolate was injected into mice via an air sac model for skin infection, organisms recovered from the spleens showed both increased expression of M and M-related proteins and increased skin-invasive potential. We show that these phenotypic changes were not solely the result of increased transcription of the mRNAs encoding the M and M-related gene products. Rather, the altered expression was associated with posttranslational modifications of the M and M-related proteins that occur in this strain, based on the presence or absence of another virulence protein, the streptococcal cysteine protease SpeB. The phenotypic variability also correlates with colony size variation. Large colonies selected by both regimens expressed more hyaluronic acid, which may explain differences in colony morphology. All large-colony variants were SpeB negative and expressed three distinct immunoglobulin G (IgG)-binding proteins in the M and M-related protein family. Small-colony variants were SpeB positive and bound little IgG through their M and M-related proteins because these proteins, although made, were degraded or altered in profile by the SpeB protease. We conclude that passage in either human blood or a mouse selects for a stable, phase-varied strain of group A streptococci which is altered in many virulence properties.

Citing Articles

Immunomodulating Enzymes from -In Pathogenesis, as Biotechnological Tools, and as Biological Drugs.

Happonen L, Collin M Microorganisms. 2024; 12(1).

PMID: 38258026 PMC: 10818452. DOI: 10.3390/microorganisms12010200.


Streptolysin O concentration and activity is central to in vivo phenotype and disease outcome in Group A Streptococcus infection.

Clarke J, Baltazar M, Alsahag M, Panagiotou S, Pouget M, Paxton W Sci Rep. 2021; 11(1):19011.

PMID: 34561464 PMC: 8463576. DOI: 10.1038/s41598-021-97866-4.


Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.

Pence M, Rooijakkers S, Cogen A, Cole J, Hollands A, Gallo R J Innate Immun. 2010; 2(6):587-95.

PMID: 20814187 PMC: 3219503. DOI: 10.1159/000317672.


Genetic switch to hypervirulence reduces colonization phenotypes of the globally disseminated group A streptococcus M1T1 clone.

Hollands A, Pence M, Timmer A, Osvath S, Turnbull L, Whitchurch C J Infect Dis. 2010; 202(1):11-9.

PMID: 20507231 PMC: 2880657. DOI: 10.1086/653124.


Generation of metabolically diverse strains of Streptococcus pyogenes during survival in stationary phase.

Wood D, Weinstein K, Podbielski A, Kreikemeyer B, Gaughan J, Valentine S J Bacteriol. 2009; 191(20):6242-52.

PMID: 19666718 PMC: 2753042. DOI: 10.1128/JB.00440-09.


References
1.
Kapur V, Majesky M, Li L, Black R, Musser J . Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A. 1993; 90(16):7676-80. PMC: 47205. DOI: 10.1073/pnas.90.16.7676. View

2.
Bernish B, van de Rijn I . Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production. J Biol Chem. 1999; 274(8):4786-93. DOI: 10.1074/jbc.274.8.4786. View

3.
Schrager H, Rheinwald J, Wessels M . Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest. 1996; 98(9):1954-8. PMC: 507637. DOI: 10.1172/JCI118998. View

4.
Schrager H, Alberti S, Cywes C, Dougherty G, Wessels M . Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest. 1998; 101(8):1708-16. PMC: 508753. DOI: 10.1172/JCI2121. View

5.
Leonard B, Woischnik M, Podbielski A . Production of stabilized virulence factor-negative variants by group A streptococci during stationary phase. Infect Immun. 1998; 66(8):3841-7. PMC: 108431. DOI: 10.1128/IAI.66.8.3841-3847.1998. View